Research Reference
Semaglutide
GLP-1 agonist — appetite suppression and weight loss (FDA-approved drug)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Semaglutide is a GLP-1 receptor agonist that suppresses appetite, delays gastric emptying, and improves glucose-dependent insulin secretion. It has extensive clinical trial data — FDA-approved for both weight loss and type 2 diabetes.
Research peptide protocols use much lower doses than pharmaceutical formulations due to variable potency and purity. Community protocols most commonly describe 250 mcg weekly, starting at 125 mcg for 2–4 weeks to assess tolerance.
Semaglutide is the active ingredient in FDA-approved products; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 3 mg vial. Resulting concentration: 1.5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.25 mg | 16.67 units | 0.17 mL | WeeklyStart dose (weeks 1–4) |
| 0.5 mg | 33.33 units | 0.33 mL | WeeklyWeeks 5–8 |
| 1 mg | 66.67 units | 0.67 mL | WeeklyWeeks 9–12 |
| 2.4 mg | 160 units | 1.6 mL | WeeklyTarget (weeks 17+) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 3 mg vial with 2 mL bacteriostatic water, the concentration is 1.5 mg/mL (1,500 mcg/mL); a 250 mcg dose draws to ~17 units (0.17 mL). For a 5 mg vial with 2 mL, the concentration is 2.5 mg/mL; a 250 mcg dose draws to 10 units (0.1 mL).
Gently swirl — do not shake. Refrigerate at 2–8°C and use within 28 days.
Cycling Protocol
Standard cycle: 250 mcg weekly for 8 weeks on, 8 weeks off. The slow titration (125 mcg weeks 1–4, then 250 mcg weeks 5–8) mimics FDA-approved protocols that emphasize gradual increases for tolerability.
Community protocols describe extensions to 12–16 weeks for weight-loss-focused cycles; a smaller subset self-report doses up to 500 mcg weekly. Community sources most commonly describe 250 mcg as sufficient for appetite suppression at the research-peptide level.
FDA-approved titration (pharmaceutical, significantly higher): 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg weekly. The STEP 1 trial showed 14.9% weight loss at 2.4 mg/week over 68 weeks (Wilding et al., 2021).
Routes of Administration
Subcutaneous injection is the only route for injectable semaglutide.
- Sites: Rotate between abdomen, thigh, and upper arm. Community sources describe the abdomen as offering the most consistent absorption.
- Volume: ~0.17 mL with an insulin syringe (29–31 gauge)
- Timing: Once weekly, same day each week in most reported protocols
- IM injection — community sources do not describe IM protocols, citing concern over faster absorption
Stacking Protocols
| Stack | Purpose | Protocol | | --- | --- | --- | | Semaglutide + AOD-9604 | Appetite suppression + direct fat metabolism | Semaglutide 250 mcg/week + AOD-9604 300 mcg/day | | Semaglutide + BPC-157 | Appetite suppression + tissue repair | Community-reported; no controlled data |
Semaglutide is typically run as a standalone metabolic protocol. Community sources describe combining it with structured nutrition and tracking body composition, fasting glucose, and lipid panels.
Side Effects & Safety
- Nausea — most common, especially during titration; typically mild-moderate and dose-dependent
- Diarrhea or constipation — common, usually transient
- Vomiting — less frequent, more common at higher doses
- Injection site reactions — mild redness or irritation
- Decreased appetite — the intended mechanism effect
- Hypoglycemia — low risk when used alone; higher with insulin or sulfonylureas
- Pancreatitis — rare but monitored (as with all GLP-1 agonists)
- Gallbladder events — cholelithiasis reported, consistent with rapid weight loss
Research-peptide and compounded forms are not FDA-approved.
Research Basis
Community research peptide doses are dramatically lower than FDA-approved pharmaceutical doses.
FDA-approved weight loss dose: 2.4 mg/week after titration (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg). The STEP 1 trial showed 14.9% weight loss at 2.4 mg/week over 68 weeks (Wilding et al., 2021, PMID 33567185).
FDA-approved diabetes dose: 0.25–1 mg/week maintenance. Cardiovascular benefit demonstrated in SUSTAIN-6 (Marso et al., 2016, PMID 27192586).
Why community doses are ~10x lower: Research peptides have variable potency and purity compared to pharmaceutical-grade semaglutide. The community starts at doses equivalent to the lowest FDA titration step (0.25 mg) and increases cautiously. Some people are highly sensitive to GLP-1 agonists — starting low allows assessment of individual tolerance.